Discussion
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation…
Discussion
The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).
Discussion
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
A short quiz focused on the stages of multiple myeloma, including how the disease is classified and what each stage indicates. It offers a clear snapshot of how myeloma can progress and what staging means for disease management.
Discussion
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Blenrep (belantamab mafodotin) in combination with other medications for hard-to-treat multiple myeloma. The…
